BCM
PDLI

BlueCrest Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

BlueCrest Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100,000
Closed -$503K – 1378
2015
Q3 		$503K Buy
+100,000
New +$573K 0.02% 593

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's PDLI Position: Q4 2019 in Review

BlueCrest Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2019, closing a stake of 26,750 shares — an estimated $58K sold.

BlueCrest Capital Management first reported a position in PDLI in Q2 2017 and held it in 5 quarters. The position peaked at $503K in Q3 2018. 150 funds tracked by Wall St. Rank hold PDLI as of Q4 2019.

  • BlueCrest Capital Management reported no remaining PDL BioPharma, Inc. position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 26,750 PDL BioPharma, Inc. shares in Q4 2019, an estimated $58K.
  • BlueCrest Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2017 and held it in 5 quarters.
  • BlueCrest Capital Management's PDL BioPharma, Inc. position peaked at $503K in Q3 2018.
  • 150 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.